First two patients treated in pilot study of NB1 bone graft device for spine fusion

Bone Biologics Corp

Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.
Study targets 30 adult subjects; design reviewed by FDA Division of Orthopedic Devices to support US pivotal trial.
Preclinical studies showed strong safety profile and fusion success; CEO cites $3 billion global spine fusion market opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.